Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Phosphate Accelerates Cellular Cholesterol Efflux in THP-1 Cells

被引:4
|
作者
Komatsu, Tomohiro [1 ,2 ]
Abe, Satomi [1 ]
Nakashima, Shihoko [3 ]
Sasaki, Kei [2 ]
Higaki, Yasuki [1 ,3 ]
Saku, Keijiro [4 ]
Miura, Shin-ichiro [4 ]
Uehara, Yoshinari [1 ,2 ,3 ,4 ]
机构
[1] Fukuoka Univ, Res Inst Phys Act, 8-19-1 Nanakuma,Johnan Ku, Fukuoka 8140180, Japan
[2] Fukuoka Univ Hosp, Ctr Prevent Antiaging & Regenerat Med, 7-45-1 Nanakuma,Johnan Ku, Fukuoka 8140180, Japan
[3] Fukuoka Univ, Fac Sports & Hlth Sci, 8-19-1 Nanakuma,Johnan Ku, Fukuoka 8140180, Japan
[4] Fukuoka Univ Hosp, Dept Cardiol, 7-45-1 Nanakuma,Johnan Ku, Fukuoka 8140180, Japan
关键词
HDL; cholesterol efflux; DPP-4; inhibitor; GLP-1; ABCA1; apoA1; CASSETTE TRANSPORTER A1; TYPE-2; DIABETES-MELLITUS; FUNCTIONAL EXPRESSION; ATHEROSCLEROTIC LESION; SIGNAL-TRANSDUCTION; INSULIN-RESISTANCE; RECEPTOR AGONIST; HDL-CHOLESTEROL; GLP-1; RECEPTOR; FATTY-ACIDS;
D O I
10.3390/biom13020228
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cholesterol efflux is a major atheroprotective function of high-density lipoproteins (HDLs) which removes cholesterol from the foam cells of lipid-rich plaques in Type 2 diabetes. The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin phosphate increases plasma glucagon-like peptide-1 (GLP-1) concentrations and is used to treat Type 2 diabetes. GLP-1 plays an important role in regulating insulin secretion and expression via the GLP-1 receptor (GLP-1R), which is expressed in pancreatic islets as well as freshly isolated human monocytes and THP-1 cells. Here, we identified a direct role of GLP-1 and DPP-4 inhibition in HDL function. Cholesterol efflux was measured in cultivated phorbol 12-myristate 13-acetate-treated THP-1 cells radiolabeled with H-3-cholesterol and stimulated with liver X receptor/retinoid X receptor agonists. Contrary to vildagliptin, sitagliptin phosphate together with GLP-1 significantly (p < 0.01) elevated apolipoprotein (apo)A1-mediated cholesterol efflux in a dose-dependent manner. The sitagliptin-induced increase in cholesterol efflux did not occur in the absence of GLP-1. In contrast, adenosine triphosphate-binding cassette transporter A1 (ABCA1) mRNA and protein expressions in the whole cell fraction were not changed by sitagliptin in the presence of GLP-1, although sitagliptin treatment significantly increased ABCA1 protein expression in the membrane fraction. Furthermore, the sitagliptin-induced, elevated efflux in the presence of GLP-1 was significantly decreased by a GLP-1R antagonist, an effect that was not observed with a protein kinase A inhibitor. To our knowledge, the present study reports for the first time that sitagliptin elevates cholesterol efflux in cultivated macrophages and may exert anti-atherosclerotic actions that are independent of improvements in glucose metabolism. Our results suggest that sitagliptin enhances HDL function by inducing a de novo HDL synthesis via cholesterol efflux.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes
    Nomiyama, Takashi
    Akehi, Yuko
    Takenoshita, Hiromasa
    Nagaishi, Ryoko
    Terawaki, Yuichi
    Nagasako, Hisahiro
    Kudo, Tadachika
    Kodera, Takehiko
    Kobayashi, Kunihisa
    Urata, Hidenori
    Yanase, Toshihiko
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2012, 95 (02) : E27 - E28
  • [32] Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34+CXCR4+ cells in patients with type 2 diabetes
    Aso, Yoshimasa
    Jojima, T.
    Iijima, T.
    Suzuki, K.
    Terasawa, T.
    Fukushima, M.
    Momobayashi, A.
    Hara, K.
    Takebayashi, K.
    Kasai, K.
    Inukai, T.
    ENDOCRINE, 2015, 50 (03) : 659 - 664
  • [33] Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34+CXCR4+ cells in patients with type 2 diabetes
    Yoshimasa Aso
    T. Jojima
    T. Iijima
    K. Suzuki
    T. Terasawa
    M. Fukushima
    A. Momobayashi
    K. Hara
    K. Takebayashi
    K. Kasai
    T. Inukai
    Endocrine, 2015, 50 : 659 - 664
  • [34] Single-Dose Pharmacokinetics and Pharmacodynamics of Sitagliptin, an Inhibitor of Dipeptidyl Peptidase-4, in Healthy Indian Male Subjects
    Sangle, Ganesh V.
    Patil, Mohan
    Deshmukh, Nitin
    Kamble, Shantibhushan
    Vuppalavanchu, Kiran Kumar
    Kale, Sushil
    Baig, Layeeq
    Singh, Geetchandra
    Shaikh, Javed
    Tripathi, Jitendra
    Aravindababu, P.
    DIABETES, 2017, 66 : A630 - A630
  • [35] Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Does Not Affect the Pharmacokinetics of Ethinyl Estradiol or Norethindrone in Healthy Female Subjects
    Migoya, Elizabeth
    Larson, Patrick
    Bergman, Arthur
    Miller, Jutta
    Johnson-Levonas, Amy O.
    Lasseter, Kenneth C.
    Wagner, John A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (09): : 1319 - 1325
  • [36] A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients
    Satoh-Asahara, Noriko
    Sasaki, Yousuke
    Wada, Hiromichi
    Tochiya, Mayu
    Iguchi, Azusa
    Nakagawachi, Reiko
    Odori, Shinji
    Kono, Shigeo
    Hasegawa, Koji
    Shimatsu, Akira
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2013, 62 (03): : 347 - 351
  • [37] Mast cells change cellular cholesterol contents and inhibit cholesterol efflux from THP-1 macrophage-derived foam cells
    Zhao, Z. Z.
    Yang, Y. Z.
    Wang, S.
    Dong, B. H.
    Wang, Z.
    Wei, D. H.
    Liu, L. S.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 539 - 539
  • [38] Effect of dipeptidyl peptidase-4 inhibitor sitagliptin on CD4+T lymphocytes and monocytes in patients with type 2 diabetes
    Hattori, A.
    Tokuyama, H.
    Shimada, F.
    Nieda, M.
    Maezawa, Y.
    Kobayashi, K.
    Kawamura, H.
    Takemoto, M.
    Yokote, K.
    DIABETOLOGIA, 2014, 57 : S373 - S373
  • [39] Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers
    Bergman, Arthur
    Mistry, Goutam C.
    Luo, Wen-Lin
    Liu, Q.
    Stone, Julie
    Wang, Amy
    Zeng, Wei
    Chen, Li
    Dilzer, Stacy
    Lasseter, Kenneth
    Herman, Gary A.
    Wagner, John A.
    Krishna, Rajesh
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2007, 28 (06) : 307 - 313
  • [40] Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus
    Iwamoto, Yasuhiko
    Taniguchi, Tadaaki
    Nonaka, Kenji
    Okamoto, Taro
    Okuyama, Kotoba
    Ferreira, Juan Camilo Arjona
    Amatruda, John
    ENDOCRINE JOURNAL, 2010, 57 (05) : 383 - 394